NCT05737732 The Ambient Light Multiple Myeloma Study
| NCT ID | NCT05737732 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Multiple Myeloma |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-02-13 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-02-13 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. While receiving these light treatments, participants' sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels and symptoms will be assessed over a 2-month period.
Eligibility Criteria
Inclusion Criteria: * Multiple Myeloma diagnosis * Scheduled to undergo their first Autologous Stem Cell Transplant procedure. * 21years or older * Able to provide informed consent. * English-language proficient Exclusion Criteria: * Previous Autologous Stem Cell Transplant procedure * Pregnancy * Eye diseases which limit the ability of light to be processed * Secondary cancer diagnosis within the last 5 years * Severe sleep disorders * History of bipolar disorder or manic episodes * Severe psychological impairment * Previous use of light therapy * Active infection including COVID-19 infection
Contact & Investigator
Mariana Figueiro, PhD
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT05737732 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05737732 currently recruiting?
Yes, NCT05737732 is actively recruiting participants. Contact the research team at Barbara.Plitnick@mountsinai.org for enrollment information.
Where is the NCT05737732 trial being conducted?
This trial is being conducted at New York, United States, New York, United States.
Who is sponsoring the NCT05737732 clinical trial?
NCT05737732 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Mariana Figueiro, PhD at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 200 participants.